Priya Hargunani’s Post

#CaretoCure #BreastCancerAwareness

Breast cancer doesn’t just impact bodies—it touches hearts, families, and communities. This October, as we observe Breast Cancer Awareness Month, let’s remember the courage of every woman who has faced this battle. 💖 For many, the road from **care** to **cure** is filled with fear, hope, and strength. Let’s stand together for our mothers, daughters, sisters, and friends who have fought, who are fighting, and who need our support. Early detection can save lives, but so can compassion and love. 💕 #BreastCancerAwareness #CareToCure #HeartAndHope #WeFightTogether #SupportAndStrength

🔬 **Advancing Breast Cancer Management through Targeted Therapies** 🌟 The fight against breast cancer has seen remarkable progress over the past three decades, but with incidence rates still on the rise, innovative prevention strategies are more crucial than ever. A recent review published in *Frontiers in Medicine* delves into the pivotal role of nuclear hormone receptors in breast cancer development and the potential of targeted therapies to prevent both HR-positive and HR-negative breast cancer. 💡 **Key Insights:** - Targeted therapies like selective ER modulators and aromatase inhibitors have shown promise in preventing HR-positive breast cancer. - The exploration of drugs targeting nuclear receptors such as RAR, RXR, and VDR opens new avenues for preventing HR-negative breast cancer. - The ongoing research is essential in reducing breast cancer incidence and the associated healthcare burden. 🔗 Read more here https://lnkd.in/dDXN_Z8c #BreastCancer #OncologyResearch #TargetedTherapies #HealthcareInnovation #FrontiersInMedicine

🔬 Rethinking Low-Grade and Low-Volume Prostate Cancer A recent Cancer Epidemiology article by Dr. Hashim Uddin Ahmed, Manit Arya, Alex Freeman, and Prof. Mark Emberton explores the nature of low-grade and low-volume prostate cancer. The study suggests that these small, low-grade lesions might not always meet the hallmarks of malignancy. Unlike larger, high-grade lesions, which are often responsible for metastatic disease, these smaller lesions might not pose the same risk. This perspective invites a reassessment of how we classify and manage low-grade prostate cancers, potentially impacting treatment strategies and patient care. Read the full article here: DOI: https://lnkd.in/dQXXX7Bn #ProstateCancer #Oncology #CancerResearch #MedicalInsights

Orchestrating the Future of Cancer Therapy: AI as the Definitive Game Changer The recent publication, *"Revolutionizing Cancer Therapy: The Role of Artificial Intelligence in Enhancing Treatment Efficacy,"* highlights the transformative potential of AI in personalizing and optimizing cancer treatment strategies. By integrating AI, clinicians can enhance treatment precision, reduce side effects, and ultimately improve patient outcomes. This marks a significant step towards the future of oncology, where technology and human expertise converge to offer hope and better care for cancer patients. Explore the full publication here: https://lnkd.in/dBA9G9Q5 #AI #CancerTherapy #Oncology #HealthcareInnovation #PrecisionMedicine

The Future of Prostate Cancer Diagnosis: AI at the Helm Imagine a world where unnecessary biopsies become a thing of the past. Thanks to groundbreaking advancements in Artificial Intelligence, this is no longer just a dream—it's becoming reality. AI's potential to differentiate between aggressive and non-aggressive prostate cancer is revolutionizing the way we approach diagnosis, sparing patients from needless procedures and anxiety. This innovation marks a significant leap towards more personalized, precise, and patient-centered care. 🌟 The intersection of technology and medicine is truly transforming lives. Curious about how AI is reshaping cancer diagnostics? Dive into the details below. ⬇️ 🔗 Explore the full article https://lnkd.in/dZ78tk3A #AIRevolution #ProstateCancer #HealthcareInnovation #FutureOfMedicine #PrecisionMedicine

🔬 **Advancing Cancer Diagnosis and Therapy with Tumor Biomarkers** 🔬 Signal Transduction and Targeted Therapy that delves into the critical role of tumor biomarkers in cancer management. The authors, highlight the significant strides made in the discovery and application of these biomarkers for early diagnosis, prognosis prediction, and targeted therapy. The article also discusses: - The evolution and history of tumor biomarkers. - Innovative technologies for biomarker detection. - The impact of biomarker-based therapies on personalized medicine. This review underscores the potential of tumor biomarkers to revolutionize cancer treatment and offers valuable insights into overcoming current challenges in the field. Read the full article for an in-depth exploration: https://lnkd.in/d2QXegx7 #CancerResearch #TumorBiomarkers #PersonalizedMedicine #TargetedTherapy #SignalTransduction #HealthcareInnovation

Breast cancer overview! A comprehensive review on FDA-approved drugs for breast cancer treatment This article covers 39 drugs, their mechanisms, side effects, and novel formulations in clinical trials. An invaluable resource for anyone in cancer research and drug development. Read more here: https://lnkd.in/daCmNaiM #BreastCancer #Pharmacology #DrugDevelopment #Oncology #HealthcareInnovation

#ASCO2024 New insights from the JCOG1607 HERB TEA Study, comparing trastuzumab emtansine (T-DM1) with the HPD regimen (trastuzumab, pertuzumab, docetaxel) in older patients with advanced HER2-positive breast cancer. Although T-DM1 did not show non-inferiority in overall survival compared to HPD, this subgroup analysis highlights the need for tailored treatment approaches for elderly patients. HPD remains the standard for advanced HER2-positive breast cancer across age groups. Read more: https://lnkd.in/d6TeQHyd #Oncology #BreastCancer #ClinicalResearch #HER2Positive #Healthcare

ASCO 2024 PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer. Add carboplatin (carbo) to anthracycline-based chemotherapy (usually AC-T) in treating high-risk patients with triple-negative breast cancer not eligible for KN-522 in the neoadjuvant setting or those higher-risk patients getting adjuvant therapy. The trial included 868 patients receiving either neoadjuvant or adjuvant AC-T who were randomized to add carbo or AC-T alone. At a median follow-up of 57.2 months, the primary endpoint was met with a significant increase in 5-year EFS in the carbo group (82.3% vs 75.1%), with a hazard ratio of 0.67 (P = .012). The OS at 5 years was higher in the carbo group (90.7% v 87%), approaching statistical significance (P = .057). Except for a higher incidence of cytopenias with carbo, toxicities were similar, with a slightly higher discontinuation rate in the carbo group (2.8% vs 0.9%). To Read more : https://lnkd.in/dX_ma3Zj #ASCO2024 #OncologyResearch #BreastCancer